With great interest, we read the brief communication by Morita et al. (1) about overall survival (OS) benefit derived from survival postprogression (SPP) rather than progression-free survival (PFS). The authors performed statistical simulations to explain why experimental treatments could bring survival benefit by prolonging SPP rather than PFS. In other words, the experimental treatment could still exert influence even after having been stopped. We would like to provide clinical interpretations that might account for Prof. Morita's findings.
First, targeted agents may induce clonal evolution among cancer cells. For example, mutated KRAS clones can emerge during cetuximab treatment in colorectal cancer patients who were previously classified as wtKRAS (2) . In addition, clonal evolution induced by cetuximab could either be reserved or reversed after cetuximab is stopped. Second, bevacizumab, another commonly used targeted agent, can increase the population of cancer stem cells (3) . Third, other angiogenesis inhibitors may also elicit malignant progression by increasing local invasion as well as distant metastasis (4) . Fourth, antitumor treatments may not only induce clonal evolution of cancer cells, but also transformation of the host. Chemotherapy-derived inflammatory response, for instance, can promote the function of immunosuppressive myeloid cells (5), thus creating a more favorable microenvironment for the tumor. In conclusion, although experimental treatments were stopped, their effects on reshaping tumor cells and patients were retained.
